Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy

Hideki Ueno, Shuichi Okada, Takuji Okusaka, Masafumi Ikeda

Research output: Contribution to journalArticlepeer-review

93 Scopus citations

Abstract

The aim of the present study was to determine prognostic factors in patients with metastatic pancreatic adenocarcinoma (PC) receiving systemic chemotherapy. The relationship between patient characteristics and prognosis was examined in 103 consecutive patients with metastatic PC. The overall median survival time and 1-year survival rate were 3.2 months and 5.6%, respectively. Among the 20 potential prognostic variables investigated, only three variables, a serum C-reactive protein (CRP) level of ≥5 mg/dl, the performance status of 2-3 and a serum carbohydrate antigen 19-9 (CA 19-9) level of ≥10,000 U/ml were identified as the factors independently associated with a shorter survival. A prognostic index based on the regression coefficients of these three factors was proposed to classify the patients into three groups, with good, intermediate and poor prognosis. The median survival time for these three groups was 5.2, 2.6 and 1.4 months, respectively. The findings of this study may be useful in determining treatment strategies and in designing future clinical trials of systemic chemotherapy for metastatic PC. Copyright (C) 2000 S. Karger AG, Basel.

Original languageEnglish
Pages (from-to)296-301
Number of pages6
JournalOncology
Volume59
Issue number4
DOIs
StatePublished - 2000
Externally publishedYes

Keywords

  • Chemotherapy
  • Metastasis
  • Pancreatic cancer
  • Prognosis
  • Prognostic factor

Fingerprint

Dive into the research topics of 'Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy'. Together they form a unique fingerprint.

Cite this